Compare ENTA & GLAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | GLAD |
|---|---|---|
| Founded | 1995 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.3M | 468.1M |
| IPO Year | 2013 | N/A |
| Metric | ENTA | GLAD |
|---|---|---|
| Price | $14.04 | $18.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $20.40 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 220.0K | 203.6K |
| Earning Date | 02-09-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 9.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.59 |
| Revenue | $66,980,000.00 | ★ $91,673,000.00 |
| Revenue This Year | $0.99 | $13.52 |
| Revenue Next Year | $0.19 | $8.34 |
| P/E Ratio | ★ N/A | $11.85 |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $4.09 | $18.58 |
| 52 Week High | $17.15 | $29.54 |
| Indicator | ENTA | GLAD |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 30.01 |
| Support Level | $13.18 | $18.65 |
| Resistance Level | $15.55 | $19.14 |
| Average True Range (ATR) | 0.66 | 0.46 |
| MACD | 0.17 | -0.19 |
| Stochastic Oscillator | 50.00 | 6.73 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.